Products
Elezanumab Biosimilar Monoclonal Antibody (RGMA) for Research
Pre-Made Elezanumab biosimilar, Whole mAb, Anti-RGMA Antibody: Anti-RGM therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Elezanumab (ABT-555) is a monoclonal antibody RGMa inhibitor being investigated to treat spinal cord injuries, multiple sclerosis and acute ischemic stroke.
Order Information
| Catalog No. | Package | List Price(In USD) | Discount off | Discount Price |
|---|---|---|---|---|
| GMP-Bios-ab-169-1mg | 1mg | 3090 |
Size： 1mg | 10mg | 100mg
Product Details
| Products Name (INN Index) | Pre-Made Elezanumab biosimilar, Whole mAb, Anti-RGMA Antibody: Anti-RGM therapeutic antibody |
| INN Name | Elezanumab |
| Target | RGMA |
| Format | Whole mAb |
| Derivation | Human |
| Species Reactivity | Human |
| CH1 Isotype | IgG1 |
| VD LC | Lambda |
| Highest_Clin_Trial (Jan '20) | Phase-II |
| Est. Status | Active |
| 100% SI Structure | None |
| 99% SI Structure | None |
| 95-98% SI Structure | None |
| Year Proposed | 2016 |
| Year Recommended | 2017 |
| Companies | AbbVie |
| Conditions Approved | na |
| Conditions Active | Multiple sclerosis;Spinal cord injuries;Stroke |
| Conditions Discontinued | na |
| Development Tech | na |
About target - RGMA
1. Protein Repulsive guidance molecule A
2. Gene RGMA
3. Organism Homo sapiens (Human)
Function
Member of the repulsive guidance molecule (RGM) family that performs several functions in the developing and adult nervous system. Regulates cephalic neural tube closure, inhibits neurite outgrowth and cortical neuron branching, and the formation of mature synapses. Binding to its receptor NEO1/neogenin induces activation of RHOA-ROCK1/Rho-kinase signaling pathway through UNC5B-ARHGEF12/LARG-PTK2/FAK1 cascade, leading to collapse of the neuronal growth cone and neurite outgrowth inhibition. Furthermore, RGMA binding to NEO1/neogenin leads to HRAS inactivation by influencing HRAS-PTK2/FAK1-AKT1 pathway. It also functions as a bone morphogenetic protein (BMP) coreceptor that may signal through SMAD1, SMAD5, and SMAD8.
